Clinical Trial Update: A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) [Phase 3]

View source ↗

Summary

A Phase 3 study of sacituzumab govitecan (Sac-TMT, MK-2870) for breast cancer is currently recruiting. The trial includes patients with triple-negative breast c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Trodelvy (sacituzumab govitecan) (sacituzumab govitecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Breast Neoplasms, Triple Negative Breast Neoplasms | Phase 3 | Status: RECRUITING